Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also issued research reports about the company. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics in a report on Thursday. Zacks Research lowered shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Stifel Nicolaus upped their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Finally, Citizens Jmp upped their price objective on shares of Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $95.78.

Structure Therapeutics Price Performance

Shares of GPCR opened at $67.06 on Friday. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The company’s fifty day moving average price is $35.52 and its 200 day moving average price is $25.79. The company has a market capitalization of $3.88 billion, a PE ratio of -54.97 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. EverSource Wealth Advisors LLC raised its position in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. State of Wyoming bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $28,000. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after buying an additional 820 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after buying an additional 2,766 shares during the period. Finally, ANTIPODES PARTNERS Ltd boosted its stake in Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.